azacitidine has been researched along with lestaurtinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gore, SD | 1 |
| Karp, J | 1 |
| Al-Jamal, HA; Hassan, R; Johan, MF; Mat Jusoh, SA | 1 |
3 other study(ies) available for azacitidine and lestaurtinib
| Article | Year |
|---|---|
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Topics: Apoptosis; Azacitidine; Carbazoles; Cell Line, Tumor; Cells, Cultured; DNA Methylation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor | 2015 |